Integrated cardiac safety assessment methodologies for noncardiac drugs in discovery, development, and postmarketing surveillance /
I tiakina i:
| Kaituhi matua: | |
|---|---|
| Kaituhi rangatōpū: | |
| Ētahi atu kaituhi: | |
| Hōputu: | Tāhiko īPukapuka |
| Reo: | Ingarihi |
| I whakaputaina: |
Hoboken, N.J. :
John Wiley & Sons,
c2009.
|
| Ngā marau: | |
| Urunga tuihono: | An electronic book accessible through the World Wide Web; click to view |
| Ngā Tūtohu: |
Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|
Rārangi ihirangi:
- The importance of cardiac safety assessments
- The biological basis of adverse drug reactions
- Cardiac structure and function
- Cardiac pathophysiology and disease
- Drug discovery and drug design
- Nonclinical development
- The thorough QT/QTc trial
- General safety assessments
- Therapeutic use trials and meta-analyses
- Assessment methodologies in nonexperimental postmarketing surveillance
- Postmarketing proarrhythmic cardiac safety assessments
- Generalized cardiac safety
- Medication errors, adherence, and concordance
- Future directions in drug safety.